ACTRN12606000010594撤回2 期
Phase II Study to Determine Predictive Markers of Response to MDX-010 (BMS-734016) in Patients with Unresectable Stage III or IV Malignant Melanoma
Bristol-Myers Squibb Pty Ltd.0 个研究点目标入组 80 人开始时间: 2006年1月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma (excluding ocular melanoma). A pre- and post-treatment fresh core or excision tumour biopsy must be provided.
排除标准
- •No exclusion criteria
研究者
相似试验
招募中
不适用
A pilot study to investigate prognostic marker of degeneration from cervical intraepithelial neoplasia to cervix carcinomaC53N87C51N90C52N89Malignant neoplasm of cervix uteriDysplasia of cervix uteriMalignant neoplasm of vulvaOther noninflammatory disorders of vulva and perineumMalignant neoplasm of vaginaOther noninflammatory disorders of vaginaDRKS00024987Carl von Ossietzky Universität/Klinikum Oldenburg; Universitätsklinik für Gynäkologie und Geburtshilfe550
招募中
不适用
A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "Colorectal cancerJPRN-UMIN000034885Japan Clinical Cancer Research Organization (JACCRO)80
进行中（未招募）
不适用
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®EUCTR2015-001569-20-Outside-EU/EEAMerck Serono Co., Ltd.214
招募中
不适用
Prospective study to identify prognostic markers of pancreatic cancerpancreatic cancerJPRN-UMIN000034022Department of Gastroenterology and Hepatology, Kochi Medical School Hospital, Kochi University150
招募中
不适用
Validation of predictive and prognostic markers in upper gastrointestinal cancerpper gastrointestinal cancerJPRN-UMIN000030472Shimane University Faculty of Medicine800